Actinic Keratoses Clinical Trial
Official title:
Noninvasive Imaging Techniques to Monitor Photosensitizer and Singlet Oxygen Levels During Photodynamic Therapy of Actinic Keratoses
The purpose of the study is to test a new video device for actinic keratoses. The device takes images of your skin lesions during the treatment, to learn whether this device can predict how well the treatment is working.
This intervention is designed to help establish what the optimal conditions are for treating actinic keratoses with photodynamic therapy (PDT). The primary outcome of this study is to determine whether the rate of singlet oxygen (sO2) production and/or the initial intralesional photosensitize (PpIX) levels, can predict the clinical responsiveness of AK lesions to PDT. Participants will receive standard red light PDT treatment, except that lesions will be carefully counted beforehand. During the window of red light illumination, photos and a video of one area of skin will be taken to allow us to monitor the progress of the treatment. Any remaining lesions will be counted upon follow-up. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03575780 -
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
|
Phase 1 | |
| Completed |
NCT04085367 -
Multicenter Study to Assess the Efficacy and Safety of Methyl Aminolevulinate Hydrochloride (MAL) 16.8% Cream (CD06809-41) Versus Vehicle Cream for Actinic Keratosis of the Face
|
Phase 3 | |
| Completed |
NCT05937529 -
Impact of Madecassoside and 5 % Panthenol Cream in Post Photodynamic Therapy for Actinic Keratosis
|
N/A | |
| Completed |
NCT02520700 -
A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses
|
N/A | |
| Terminated |
NCT01538901 -
Imiquimod Versus Photodynamic Therapy of Actinic Keratoses in Organ Transplant Recipients
|
Phase 4 | |
| Completed |
NCT01354717 -
Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo
|
Phase 3 | |
| Completed |
NCT00742391 -
A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations
|
Phase 3 | |
| Completed |
NCT03285477 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
|
Phase 3 | |
| Suspended |
NCT03963102 -
Duration of Ameluz Application in Acral Actinic Keratoses Response
|
Phase 4 | |
| Withdrawn |
NCT06026358 -
Tirbanibulin 1% Ointment for the Treatment of Actinic Keratosis on the Back of the Hands
|
Phase 4 | |
| Completed |
NCT02622594 -
Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times
|
Phase 4 | |
| Completed |
NCT00786994 -
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
|
Phase 2 | |
| Completed |
NCT00774787 -
Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses
|
Phase 4 | |
| Completed |
NCT00544258 -
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
|
Phase 1 | |
| Completed |
NCT04024579 -
Treatment of Actinic Keratosis With 5% KOH Solution
|
||
| Completed |
NCT04843553 -
Nicotinamide for Prevention of Pre-malignant Actinic Keratosis in Kidney Transplant Recipients
|
Early Phase 1 | |
| Completed |
NCT03315286 -
Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure
|
N/A | |
| Completed |
NCT03279328 -
Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents
|
Phase 4 | |
| Completed |
NCT02062853 -
Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video
|
N/A | |
| Terminated |
NCT01532453 -
Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients
|
Phase 3 |